Brief: Ascletis Announces Ind Filing Of Its Second Fasn Inhibitor Asc60 For Advanced Solid Tumors Accepted By China Nmpa
26/01/2022 11:15
Jan 26 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES IND FILING OF ITS SECOND FASN INHIBITOR
ASC60
FOR ADVANCED SOLID TUMORS ACCEPTED BY CHINA NMPA
Source text for Eikon: ID:nPn8qTcxa
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management